Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

EMA accepts Astellas filing for review of prostate cancer drug

Astellas Pharma announced that the European Medicines Agency (EMA) has validated and started the review process for Astellas’ application for a Type II Variation for enzalutamide.

argenx obtained a €2.5 million grant to develop antibody-based therapies

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies, received a €2.5 million grant from Flanders Innovation and Entrepreneurship (VLAIO).

Chinese biotech appears as a significant player in CAR-T therapy field

gene therapy
GenScript’s shares have risen more than sixfold since June, when it reported positive results from early studies in 35 patients with a type of blood cancer.

Immutep starts a clinical trial collaboration with MSD

Immutep, a leading Australian biotechnology company, announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of Immutep’s lead immunotherapy product

Convert Pharmaceuticals received €13.6 million for cancer drugs development

cancer treatment
Convert Pharmaceuticals has been granted a total of EUR 13,6 million in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure.

Samsung Bioepis biosimilar cancer drug begun to sell in Europe

Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).

Pfizer closes its partnership with CytomX Therapeutics

lab research
Pfizer has terminated its five-year-old partnership with CytomX Therapeutics to use its Probody drug-development platform to develop and commercialize several antibody–drug conjugates (ADCs) for cancer.

Theradex Oncology released a clinical trial management system

Theradex Oncology, a global provider in early-phase oncology management services, announced the release of their clinical trial management system (CTMS), that combines data, processes, and reports on a single platform.

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy

Eisai Co., Ltd. and MSD agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.

EMA gives orphan drug designation to Tocagen medicines

The European Medicines Agency has granted orphan medicinal product (orphan drug) designation to Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine)

Aptose Biosciences collaborates with OHM Oncology

cancer lab diagnostic
Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, announced an exclusive global license agreement with OHM Oncology

Artios Pharma in-licensed a drug development program from Masaryk University

Artios Pharma, a leading DNA Damage Response company, announced that it has exercised its option to in-license the first nuclease drug development program under its collaboration with Masaryk University in the Czech Republic.

BIOCAD leads the sales of anti-tumor drugs

For January-December 2017, BIOCAD retains, for the second year in a row, the leadership in the segment of public budget procurement (by taking into account the data on all drugs) in ruble terms and in final prices.

Median Technologies and CMIC Holdings entered into a collaborative agreement

test tube
Median Technologies, the leading Imaging Phenomics Company and CMIC HOLDINGS, a leading Contract Research Organization with services for development, manufacturing, sales and marketing, announced a collaborative agreement

Tbilisi held a conference dedicated to cancer immunotherapy

Tbilisi held a Scientific Conference “Cancer Immunotherapy – New Paradigm in Cancer Treatment”. The conference was organized by Roche and connected to the introduction of the immunotherapy drug onto the Georgian market.

Fujifilm will build a new liposome drugs manufacturing facility

FUJIFILM Corporation will invest approximately $37 million in the pharmaceutical production site of its group company, Toyama Chemical Co., Ltd., to build a new manufacturing facility in Toyama prefecture, Japan.